Login / Signup
Marc Pfeffer presented the results of PARADISE-MI at ACC last week. As discussed previously on CVCTCardiobrief, sacubitril/valsartan did not reduce the primary outcome compared to…
Meet Spironolactone and Eplerenone’s Cardio-kidney Cousin, Finerenone
Spironolactone and eplerenone improve outcomes in heart failure. Finerenone is the newest mineralocorticoid receptor antagonist and is being tested for treatment of chronic kidney disease…
Preliminary Musings on PARADISE-MI (sacubitril-valsartan post MI)
Cardiologists have been happily prescribing angiotensin receptor neprilysin inhibitor, sacubitril-valsartan, for heart failure with reduced ejection (HFrEF) for a while now. And the drug was…
A Brand New Drug for Heart Failure with Reduced Ejection Fraction: An Interview with Javed Butler about Vericiguat
Faiez Zannad speaks to Javed Butler about the FDA approval of new drug, vericiguat, for heart failure with reduced ejection fraction, following the publication of…
Global Trials Summit 2021: An Interview with John McMurray
Faiez Zannad speaks to John McMurray about the Global Trials Summit being held virtually on 12th and 13th February 2021. Register here : https://global-trials-summit.hubilo.com/
CVCT Forum 2020: An Interview with John Teerlink about Omecamtiv
What’s unique about omecamtiv? Darrel Francis speaks to GALACTIC-HF PI, John Teerlink about that dirty word in heart failure… “inotrope”. The new language is myotropes,…
CVCT Forum 2020: An Interview with Paul Armstrong about Vericiguat
Darrel Francis speaks to Paul Armstrong, PI of the VICTORIA trial, about the mechanism of new heart failure drug, Vericiguat, and the trial’s unusual power calculation: “The trial was deliberately overpowered on the primary endpoint”.
CVCT Forum 2020 Teaser: Darrel Francis interview with Faiez Zannad on Meta-Analysis Interpretation
Darrel Francis speaks to Faiez Zannad about his meta-analysis of SGLT2 inhibitors for heart failure with reduced ejection fraction published inThe Lancet. This interview takes you through the key components of the meta-analysis: Forest plots, what to make of the heterogeneity of effect, and subgroup analyses.
New drugs for Heart Failure: “My cup runneth over”
The therapy of patients with Heart Failure with reduced ejection fraction (HFrEF) has evolved over the past several decades. Beta blockers; ACEIs, ARBs or sacubutril/valsartan; along with a MRA; a loop diuretic; and hydralazine/ISDN (in African Americans) form the basis of current guideline recommended therapy. Despite their use, even when appropriately dosed at target levels, there remains a considerable incidence of hospitalizations for Heart Failure (HHF) and cardiovascular mortality (CVM) as well as compromised quality of life and increased health care costs.
Darrel Francis Interview with Milton Packer : the EMPEROR-Reduced Trial, the Patients and the Endpoints
How do triallists decide the two key features of a trial: which patients and what endpoints? And what is the future for SGLT2 inhibitors in…